Abstract
Oncogene directed therapy and immune checkpoint inhibitor therapies (ICI) resulted in a paradigm shift in non-small cell lung carcinoma (NSCLC) management. With improved survival and extra cranial control, increased likelihood of brain metastasis (BM) is reported. Several clinical trials are evaluating targeted therapy or immunotherapy in BM in lung cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
